• 2-NBDG in Sorafenib-Resistant HCC

  2026-08-14

  Sorafenib resistance in hepatocellular carcinoma is shaped by interconnected lipid and nutrient pathways. This thought-leadership article examines how the 2-NBDG Glucose Uptake Assay Kit can add a direct, non-radioactive readout of cellular glucose transporter activity to studies of HNF4A-AS1, DECR1, ferroptosis, and treatment response—while clearly distinguishing a testable metabolic hypothesis from mechanisms already established in the literature.

• Dual-Action Kinase Inhibitors and p38α Dephosphorylation

  2026-08-14

  The reference preprint shows that selected kinase inhibitors can do more than block p38α MAP kinase catalysis: they can also accelerate WIP1-mediated dephosphorylation of the activation loop. Biochemical and X-ray structural data connect this effect to an inhibitor-stabilized kinase conformation that exposes phospho-threonine, suggesting a strategy for improving inhibitor potency and signaling specificity.

• DeferoxamineB in Ferroptosis Workflows

  2026-08-13

  DeferoxamineB makes iron availability a controllable variable in cancer cell assays, helping researchers distinguish iron-dependent lipid damage from copper-driven cytotoxicity. This practical guide connects Deferoxamine to metabolic intervention studies with preparation, dosing, readout, and troubleshooting strategies.

• BML-277 Chk2 Inhibitor Workflows

  2026-08-13

  BML-277 enables controlled interrogation of ATP-competitive Chk2 signaling in biochemical assays and radiation-stressed T-cell models. This practical guide connects target engagement, radiation-induced apoptosis inhibition, and emerging cGAS–Chk2 genome-integrity biology while emphasizing controls, dosing logic, and troubleshooting.

• Zosuquidar: A Context-Aware MDR Assay Guide

  2026-08-12

  Zosuquidar and LY335979 are selective tools for studying P-glycoprotein-mediated multidrug resistance in cancer. This guide adds a disease-state-aware pharmacokinetic framework, showing how transporter expression, intracellular exposure, and assay design influence MDR reversal results.

• Interpreting In Vitro Cancer Drug Responses

  2026-08-12

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these readouts capture overlapping but non-equivalent dimensions of cancer drug response. The framework improves interpretation of growth inhibition, cell death, and response timing, with practical implications for designing more informative in vitro pharmacology studies.

• Rapamycin Workflows for mTOR Translation Studies

  2026-08-11

  Rapamycin (Sirolimus) enables controlled interrogation of mTOR-dependent growth, translation, immune activation, and disease phenotypes at nanomolar concentrations. This practical guide connects dosing and readout design with CDK4-mediated, rapamycin-resistant 4E-BP1 regulation, helping researchers distinguish pathway failure from biological compensation.

• CLK2 and Platinum Resistance in Ovarian Cancer

  2026-08-11

  A 2024 MedComm study identifies Cdc2-like kinase 2 (CLK2) as a determinant of platinum resistance in ovarian cancer and links this phenotype to phosphorylation of BRCA1 at Ser1423. The work connects CLK2 activity with enhanced DNA damage repair and provides a mechanistic framework for evaluating CLK2-directed strategies in resistant disease models.

• Laminin (925-933): Protocol and QC Guide

  2026-08-10

  Laminin (925-933) is a defined Laminin B1 chain peptide for controlled cell attachment and migration experiments, helping researchers separate ligand-specific effects from those of complex extracellular matrix preparations. It is intended for in vitro scientific research only and should not be used to support diagnostic, therapeutic, or broad metastasis-related conclusions.

• Cy5 Goat Anti-Mouse IgG (H+L) Antibody Workflow

  2026-08-09

  Build sensitive, flexible fluorescence workflows for IHC, ICC, and flow cytometry with a Cy5-conjugated secondary antibody engineered for mouse IgG detection. This guide connects practical assay design with bone-regeneration research, including lithium-treated BMSC exosomes, Wnt10a trafficking, and β-catenin localization.

• Lithium, Rab11a, and Exosomal Wnt10a in Osteogenesis

  2026-08-08

  The reference study identifies a mechanistic pathway by which lithium enhances bone mesenchymal stem cell osteogenesis: MARK2-dependent Rab11a/Rab11FIP1 trafficking increases exosomal Wnt10a secretion and activates Wnt/β-catenin signaling. Lithium-conditioned exosomes, particularly when incorporated into GelMA hydrogels, improved osteogenic responses and bone repair compared with control exosomes, providing a rationale for engineered exosome-based regeneration strategies.

• BMS-345541: Mapping NF-κB in Angiogenesis

  2026-08-07

  BMS-345541 is a selective IKK-1/IKK-2 inhibitor for resolving how NF-κB shapes cytokine responses, endothelial behavior, and tumor-cell survival. This article translates vascular findings into practical assay decisions while distinguishing pathway causality from nonspecific toxicity.

• lncRNA HNF4A-AS1 Modulates Sorafenib Resistance via Lipid Me

  2026-08-07

  The referenced study elucidates how decreased levels of the liver-enriched lncRNA HNF4A-AS1 drive resistance to sorafenib-induced ferroptosis in hepatocellular carcinoma (HCC) by reprogramming lipid metabolism. These findings identify HNF4A-AS1 as a regulator of PUFA levels and a potential therapeutic target for overcoming drug resistance in HCC.

• 2-NBDG Glucose Uptake Assay Kit in Cancer Metabolism and Sor

  2026-08-06

  Explore how the 2-NBDG Glucose Uptake Assay Kit revolutionizes single-cell glucose metabolism research, with unique insights into its role in uncovering mechanisms of sorafenib resistance in hepatocellular carcinoma. This article provides an advanced, protocol-driven perspective for cancer and metabolic disease studies.

• TREM2–ERK/p38 Axis in Microglial Regulation During Autoimmun

  2026-08-06

  This study uncovers a regulatory role for TREM2 in controlling microglial activation and inflammation in experimental autoimmune uveitis (EAU) via the ERK/p38 MAPK pathway. These findings clarify the molecular mechanisms underlying immune cell dynamics in uveitis, suggesting new avenues for targeted immunomodulation in ocular autoimmunity.

14809 records 1/988 page Next 12345 下5页 Last page